CCO Management Series
Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies
Cardiovascular Risk in HIV: Disease- and Treatment-Related Mechanisms in the HAART ERA |
Module 1 of 4 |
|
|
|
Peter Reiss, MD, PhD, discusses current understanding of the factors involved in increased cardiovascular disease risk and mortality associated with both HIV itself and treatment-related risk factors such as dyslipidemia.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the epidemiology of dyslipidemia and other cardiovascular risk factors in HIV-infected patients
- Review the association between specific antiretroviral agents and cardiovascular risk factors
- Describe the significance of traditional cardiovascular risk factors in HIV-infected patients
|
Practical Approaches to Evaluating and Monitoring Cardiovascular Risk in HIV-Infected Patients |
Module 2 of 4 |
|
|
|
James H. Stein, MD, discusses practical methods and strategies for evaluating and monitoring risk for cardiovascular disease and mortality in HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe strategies for evaluating cardiovascular risk in HIV-infected patients
- Review the application of patient risk based on age, total cholesterol level, high density lipoprotein cholesterol level, smoking, and systolic blood pressure derived from the general population to the HIV-infected population
- Discuss emerging cardiovascular risk parameters and how they may play a role in assessment of cardiovascular risk in HIV-infected patients
|
HAART and the Heart: Managing Cardiovascular Risk Through Antiretroviral Individualization |
Module 3 of 4 |
|
|
|
Stefan Mauss, MD, PhD reviews options and outcomes of individual components of antiretroviral therapy on cardiovascular risk in HIV patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the practical implications of the varying lipid effects of antiretroviral agents for treatment strategies using these agents
- Review the impact of cardiovascular risk assessment on the choice of first-line antiretroviral regimens and the use of switch strategies
- Describe the results of comparative studies of the impact of different agents and different switches between agents on cardiovascular risk factors
|
Application of Non–HIV-Specific Management Strategies for Dyslipidemia in HIV-Infected Patients |
Module 4 of 4 |
|
|
|
Pablo Tebas, MD, reviews the application of strategies used in the non–HIV-infected population for the management of dyslipidemia in HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss lipid management strategies in the setting of HIV infection, including discussion of complications that arise in the context of antiretroviral therapy
- Discuss the data on the outcomes of therapy with fibrates and statins in HIV-infected patients
- Describe the use of nonpharmacologic interventions and the impact relative to lipid-lowering therapy
|
Interactive Case Challenges
HAART Initiation in an Overweight Female With Advanced HIV Disease
|
|
|
William G. Powderly, MD, discusses a case study exploring lipid abnormalities in patients with HIV infection and strategies for their management.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify antiretroviral regimens recommended for use in treatment-naive patients with advanced HIV disease
- Explain strategies for addressing cardiovascular disease risk in patients with HIV infection
- Discuss management of hypertriglyceridemia in patients with HIV infection
|
Management of a 45-Year-Old, HIV-Infected Man With Dyslipidemia While on HAART
|
|
|
Peter Reiss, MD, PhD, presents an interactive case exploring the optimal management of an HIV-infected patient on zidovudine/lamivudine plus lopinavir/ritonavir for 3 years who presents with concerns of increased risk of heart disease associated with long-term HAART.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review recommendations for assessing cardiovascular risk and managing dyslipidemia in HIV-infected patients on HAART
- Describe the impact of switching PIs on dyslipidemia in HIV-infected patients receiving HAART
- Discuss the impact of switching NRTIs on dyslipidemia and lipoatrophy in HIV-infected patients receiving HAART
|
Management of Dyslipidemia in a 55-Year-Old Man at Very High Cardiovascular Risk
 
- Judith S. Currier, MD, MSc
- Jesse Currier, MD
|
|
|
Judith S. Currier, MD, MSc, and Jesse Currier, MD, explore strategies to control dyslipidemia in a man with multiple cardiovascular risk factors.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall the data from cohort studies regarding cardiovascular risk in HIV-infected patients
- Discuss the use of lipid-lowering agents in HIV-infected patients with dyslipidemia
- Describe selected drug-drug interactions between lipid-lowering drugs and antiretroviral agents
|
Interactive Tool
Lipid Effects of Antiretroviral Therapy
|
|
Understanding the potential for dyslipidemia or other cardiovascular risk factors while determining an appropriate HAART regimen
This tool enables you to review data from controlled studies on the lipid effects of recommended antiretroviral regimens for initial therapy as well as ‘switch strategies’ in patients on suppressive antiretroviral therapy.
You can also view a convenient graphical summary of the key data from those studies and print the data and/or download corresponding slides.
Format: HTML
|
CCO Slidesets
Dyslipidemia and Other Cardiovascular Risk Factors in HIV
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 1.80 MB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|